PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER- COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN ...
Abstract
Authors
H Miadi-Fargier C Le Pen MC Woronoff-Lemsi JP Guastalla X Pivot H Roché F Pinguet B Favier J Gligorov I Debrix M Spielmann EC Antoine M Cadilhac GA De Pouvourville